Spikevax

Manufactured by AstraZeneca

Spikevax is a laboratory equipment product manufactured by AstraZeneca. It is designed to perform specific functions within a controlled laboratory environment, but a detailed description cannot be provided while maintaining an unbiased and factual approach without extrapolation on its intended use.

Automatically generated - may contain errors

Lab products found in correlation

Vaxzevria, by AstraZeneca (1 mentions) Chadox1 ncov 19 vaccine, by AstraZeneca (1 mentions)

2 protocols using spikevax

SARS-CoV-2 Vaccination Efficacy in HSCT Patients

Check if the same lab product or an alternative is used in the 5 most similar protocols

This is an observational, prospective study performed in a single center (Hospital Universitario Ramón y Cajal, Madrid, Spain) that included 29 individuals diagnosed with OHD who were subjected to HSCT after having received the complete vaccination schedule against SARS-CoV-2. These individuals were recruited between April and June 2021, according to the following inclusion criteria: to be over 18 years old and to have been vaccinated with 1–3 doses of one of the EMA/FDA approved vaccines (Comirnaty, BioNTech/Pfizer; Spikevax, Moderna; Vaxzevria, AstraZeneca) before being subjected to HSCT for the treatment of their OHD between June 2021 and January 2022. Whole blood samples were obtained from the participants before starting the conditioning and 2.5 months after transplantation.
Eighteen individuals without OHD who were vaccinated against SARS-CoV-2 infection were recruited as healthy donors. They presented similar characteristics to HSCT individuals in terms of age, gender, and time from vaccination to sampling.

Rodríguez-Mora S., Pérez-Lamas L., Sainero M.S., Torres M., Sánchez-Menéndez C., Corona M., Mateos E., Casado-Fernández G., Alcamí J., García-Pérez J., Pérez-Olmeda M., Murciano-Antón M.A., López-Jiménez J., García-Gutiérrez V, & Coiras M. (2023). Persistent Immunity against SARS-CoV-2 in Individuals with Oncohematological Diseases Who Underwent Autologous or Allogeneic Stem Cell Transplantation after Vaccination. Cancers, 15(8), 2344.

+ Open protocol

+ Expand

Immune Response Profiling in Vaccinated HCWs

Check if the same lab product or an alternative is used in the 5 most similar protocols

In this study, the population recruited includes healthcare workers (HCW) professionals who joined voluntarily to the study from March 2022 to June 2022. All HCW have been previously vaccinated with three doses of COVID-19 vaccine [Pfizer/BNT162b2 mRNA vaccine, Spikevax (mRNA-1273); ChAdOx1 nCoV-19 vaccine (AZD1222, AstraZeneca)] and underwent a periodical screening for SARS-CoV-2 (every 2 or 3 weeks) by means of rapid antigen testing or molecular rRT-PCR testing. For all patients, demographical characteristics, the date of the vaccination and the type of vaccines were also recorded, as well as the possible date for previous SARS-CoV-2 infection.
Each subject was asked to donate two tubes of whole blood in Li-He (BD Vacutainer LH 102 I.U. 6 mL, Ref. In this study, we alternatively used the day of the last vaccination or the day of the last positivity (the latter when vaccination occurred after COVID-19 infection) to determine the effect of the time of infection or positivity on cellular or humoral immunity.

Cosma C., Galla L., Padoan A., Furlan G., Marchioro L., Zaninotto M., Basso D, & Plebani M. (2023). SARS-CoV-2 specific T-cell humoral response assessment after COVID-19 vaccination using a rapid direct real-time PCR amplification. Clinical chemistry and laboratory medicine, 61(9).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!